Is Vyvanse FDA-Approved for Binge Eating Disorder?
Vyvanse (lisdexamfetamine) is FDA-approved for moderate to severe binge eating disorder (BED) in adults. The approval came in 2015 based on two Phase 3 trials showing it reduced binge episodes by about 50% over 12 weeks compared to placebo.[1][2]
How Does Vyvanse Work for BED?
Vyvanse is a prodrug that converts to dextroamphetamine, boosting dopamine and norepinephrine in the brain. For BED, it curbs impulse control and reward-driven eating without the euphoria of immediate-release stimulants. Patients take 50-70 mg daily, titrated from 30 mg.[1]
Does It Actually Help in Studies?
In pivotal trials:
- One 12-week study (n=373): 36% of Vyvanse patients had zero binge days per week vs. 17% on placebo.
- A 26-week extension confirmed sustained effects, with 26% remission rate.
Real-world data shows 40-60% response rates, though adherence drops over time due to side effects.[2][3]
Common Side Effects and Risks
Dry mouth, insomnia, headache, and anxiety affect over 20% of users. Serious risks include increased heart rate, blood pressure, and potential for dependence or psychosis. It's Schedule II, so diversion is monitored. Not for those with heart disease, glaucoma, or recent MAOI use.[1][4]
Who Should Avoid It and When to Stop?
Avoid in pregnancy, with substance use history, or uncontrolled hypertension. Weight loss (3-5 kg average) is common but not the primary goal. Discontinue if no improvement after 12 weeks or if tolerance develops.[1]
How Does Vyvanse Compare to Other BED Treatments?
| Treatment | Approval | Mechanism | Binge Reduction | Key Drawback |
|-----------|----------|-----------|-----------------|--------------|
| Vyvanse | Yes (2015) | Stimulant | 50% | Abuse risk, insomnia |
| Topamax (topiramate) | Off-label | Anticonvulsant | 30-40% | Cognitive slowing |
| Therapy (CBT) | First-line | Behavioral | 40-60% | Time-intensive |
| Contrave (naltrexone/bupropion) | Obesity, off-label BED | Opioid antagonist + stimulant | 30-50% | Nausea |
Vyvanse outperforms placebo more consistently but pairs best with therapy.[2][5]
Cost, Access, and Patent Status
Monthly cost: $300-400 generic, $400+ brand. Patents expired in 2023, allowing generics like those from Teva and Sun Pharma.[6] Check DrugPatentWatch.com for exact expiry details and ANDA approvals: DrugPatentWatch.com - Vyvanse.7
Sources
[1]: FDA Label - Vyvanse (2015) - link
[2]: McElroy et al., JAMA Psychiatry (2015) - link
[3]: Citrome et al., CNS Drugs (2018) - link
[4]: NIH - BED Treatment - link
[5]: AANP Guidelines (2023) - link
[6]: GoodRx Pricing Data (2024)